Compound guide · Tier C
Semax
A genuinely registered medicine, in one country, resting on a literature that has never been independently replicated outside the research network that produced it.
The short answer
Semax is the hardest tiering call in this catalogue and we have placed it at C deliberately. It is not folklore: it has a real Russian marketing authorisation dating to 1996, it sits on Russia's essential medicines list, and it has been used clinically for decades, mostly in stroke recovery and cognitive disorders. That is more than almost anything else here can claim. What it does not have is independent replication. The clinical literature is overwhelmingly Russian language, produced largely within the network that developed the compound, and it has not been reproduced by trial groups elsewhere. Our Tier C definition covers single network research without independent replication, and that is what this is. The tier is not a dismissal of a regulator, it is a statement about the evidence available to read.
At a glance
| Class | Synthetic heptapeptide analogue of ACTH(4-7) |
| Developer | Institute of Molecular Genetics, Russian Academy of Sciences |
| Sold as | Semax (Семакс), registered in Russia |
| Regulatory status | Registered in Russia and nowhere else. Semax holds Russian marketing authorisation, granted in 1996 for cognitive indications and extended in 2011 to stroke, and it appears on Russia's List of Vital and Essential Medicines. It has no FDA, EMA, MHRA or TGA approval, and it is not available as a licensed medicine in any Western market. |
| Compounding status | There is no approved Semax product outside Russia to compound an equivalent of, and no Western regulator has evaluated it. |
| Anti-doping | Not specifically named on the prohibited list. Check the list as published each year if competing in tested sport. |
| Our evidence tier | Tier C. Weak human data |
What it is
Semax is a synthetic heptapeptide based on the ACTH(4-7) fragment with a Pro-Gly-Pro tail added to resist enzymatic breakdown. The parent fragment is the part of adrenocorticotropic hormone associated with effects on attention and memory rather than with the hormonal actions of ACTH. It is reported to influence BDNF expression, which is the mechanism most often cited in support of its nootropic claims.
Who it is for, and who actually takes it
In Russia, the registered indications cover cognitive disorders and stroke, with clinical use concentrated in neurology. Elsewhere there is no approved population because there is no approval.
It is bought by healthy adults for focus, cognition and mood, typically intranasally, on the strength of a registration granted for neurological patients in one country and a literature most buyers cannot read in the original.
What the research shows
The controlled data sits in a literature we cannot independently verify and would not present as a chart alongside trials whose full protocols and results are public. Charting it would give it a visual authority the evidence does not support.
Dosing
We report only what published research used. The Russian clinical literature describes intranasal administration in neurological indications, principally stroke and cognitive impairment, at concentrations formulated as a nasal solution rather than as reconstituted powder. Those parameters belong to studies conducted in patients, published in a literature that has not been independently replicated, and they are recorded here as research context rather than as a protocol. We publish no schedule and no reconstitution guidance.
What happens when you come off it
There is no adequate discontinuation data outside the Russian clinical literature, and no controlled Western trial to describe what happens when healthy users stop. Reports of tolerance or withdrawal are anecdotal.
What it is being studied for
| Area | Stage of evidence |
|---|---|
| Ischaemic stroke | Registered indication in Russia, 2011 |
| Cognitive disorders | Registered indication in Russia, 1996 |
| Optic nerve disease | Studied within the Russian literature |
| Cognition in healthy adults | No independently replicated controlled evidence |
| Anxiety and mood | Largely attributed to Selank rather than Semax |
The registration is real. The independent replication is what is missing, and for a compound in clinical use since the 1990s the absence of Western replication after thirty years is itself worth weighing, in either direction.
Common myths
Semax is approved, so it works.
It is approved in Russia, by Russian regulators, on a Russian evidence base. Approval standards and the transparency of the underlying data differ between jurisdictions, and no Western regulator has assessed it. Treating a national registration as universal validation skips that step.
There is loads of research on Semax.
There is a substantial literature and it is concentrated in Russian language journals, produced largely by the network that developed the compound. Volume of publication and independence of publication are different things, and the second one is what replication means.
It raises BDNF, so it improves cognition.
BDNF expression is a mechanism, and mechanisms are hypotheses about why something might work rather than evidence that it does. No independently replicated controlled trial has shown a cognitive benefit in healthy adults.
Intranasal is safer than injecting, so the risk is low.
Route affects absorption, not the quality of the evidence behind the compound, and it does not make an unlicensed product manufactured for research a medicine.
Verifying a purchase
Semax is a short heptapeptide, so substitution rather than contamination is the identity risk, and the Pro-Gly-Pro extension is the part that distinguishes it from the plain ACTH fragment. Require mass spectrometry rather than an HPLC figure alone. Watch content as well: the published lot report for this vendor measured 10.93 mg against a 10 mg label, an overfill of around 9%.
The general method is set out in our guide to reading a certificate of analysis, which covers the eleven checks that apply to any compound. The points above are the ones specific to Semax.
Caveats and safety
There is no Western safety database. The Russian clinical experience is long and it is not accessible for independent scrutiny in the way an FDA or EMA dossier would be. As an ACTH derived peptide it is worth noting that the fragment was selected specifically to avoid the hormonal actions of the parent, which is a design intention rather than a demonstrated separation in every user.
Where to get it
Where to get it
CertaPeptides Romania, EU. Volume discounts at 3+, 5+ and 10+ units.
| Vial | Price |
|---|---|
| 5 mg | €29.99 |
| 10 mg | €39.99 |
| 30 mg | €109.99 |
Stated purity. ≥98% stated batch specification. Published lot report #212155 returned 99.48% on a 10 mg vial, with 10.93 mg measured against a 10 mg label, which is 109.3% of the stated content.
Documentation. Selected lots independently tested by Janoshik Analytical (Czech Republic), HPLC plus mass spectrometry, reports searchable on the Janoshik public portal and at certapeptides.com/verify.
Semax is sold as laboratory research material. The vendor states it is not for human consumption and that it is not approved by the FDA, the EMA or any other regulator for use in humans or animals. Read the evidence tier at the top of this page before the price.
View Semax at CertaPeptidesAffiliate link. We earn a commission if you buy, at no extra cost to you. It does not change a word of the assessment above. Every product we have priced, in one list.
Sources
- Semax literature, PubMed
- Registered semax trials, ClinicalTrials.gov
- European Medicines Agency medicine records, for absence of authorisation
- Drugs@FDA, for absence of approval
Related compounds
Disclosure. PeptoPurity is an affiliate of CertaPeptides and earns a commission on qualifying purchases made through the vendor link on this page, at no additional cost to you. That relationship does not set the evidence tier, alter the verdict, or change a word of the assessment. Our Tier C and Tier D pages carry the same links as our Tier A pages, with the same conclusions we would publish if we earned nothing. Where the registered, prescribed route is the better option, we say so on the page that would otherwise pay us.
Scope. This is an evidence review, not medical advice. Where an approved label schedule is reproduced it is a record of what a regulator has published about a licensed medicine, not a recommendation and not a schedule for anyone to follow unsupervised. For unapproved compounds we report only the doses used in published studies, attributed to those studies, and we publish no protocols and no reconstitution guidance for any compound. Regulatory status differs between countries and changes over time. Material sold for laboratory research is not approved for human use. Decisions about treatment belong with a qualified prescriber.